Teprotumumab vs. steroids after eye decompression surgery for thyroid disease
Treatments studied
Part of Brain & nervous system, Eyes & vision, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests whether teprotumumab (a monoclonal antibody medication) works better than high-dose steroids after urgent eye socket surgery in patients with thyroid eye disease affecting the optic nerve. The goal is to prevent vision loss and improve eye symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years
- Diagnosed with thyroid eye disease with optic nerve compression (confirmed by imaging and vision loss)
- Need urgent eye socket decompression surgery because steroids didn't help or you can't take steroids
- Thyroid function normal or only mildly abnormal, and liver/kidney blood tests acceptable
- No recent eye or orbit surgery, radiation, or other immunosuppressive medications
- If female of childbearing age: negative pregnancy test and agreement to use contraception for 90 days after treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if the drug teprotumumab can help with symptoms of thyroid eye disease, such as bulging eyes, pain, or double vision. It is for adults who are beneficiaries of the Department of Defense (DOD).
This study compares two different treatment plans for Thyroid Eye Disease (TED): the standard 8 infusions of Tepezza versus a shorter 4-infusion course. It aims to see if 4 treatments might work just as well and be safer, but only for people who already respond well after the first 4 doses.
This study offers continued treatment with MHB018A for patients with thyroid eye disease (swelling and bulging of the eyes from thyroid problems) who either didn't improve enough after 24 weeks of treatment or whose symptoms came back. The goal is to see if more treatment can help reduce eye bulging and other symptoms.
This trial tests a new drug called MHB018A for chronic thyroid eye disease (TED)—a condition where the eyes become inflamed and swollen due to thyroid problems. The study aims to see if this treatment can reduce eye inflammation and improve symptoms in people who have had TED for over a year.
This study tests whether tofacitinib, a new type of immune-modulating medication, can help people with moderate-to-severe thyroid eye disease (Graves' orbitopathy) whose eyes haven't improved with standard steroid treatments. The goal is to reduce eye swelling, bulging, and inflammation that affects daily life.
This study tests an investigational medication for thyroid eye disease, which causes bulging eyes and discomfort. The treatment is given as an injection near the eye, and the study will last about 12 months to see how safe and effective it is.
Hear when a new Thyroid Eye Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.